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tings. Descriptive statistics were used to look at items of interest. Results: There 
were 1403 discharges meeting the inclusion criterion. These were linked to 1402 ER 
discharges previous to the surgery. There were no significant differences between 
the genders in terms of characteristics like race, primary payer, age, etc. However, 
more men had ER visits than women (52.43% vs 47.57%). The top diagnosis in the 
ER consisted of conduction disorders (21.03%). Syncope occurred in 10.05% of dis-
charges. Atrial fibrillation was the only ER diagnosis which women experienced 
more than men. ConClusions: The findings of the study were inconclusive in 
showing significant differences between the genders in terms of characteristics 
and ER diagnosis among recipients of primary pacemaker.
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objeCtives: To estimate low-density lipoprotein cholesterol (LDL-C) goal attainment 
in patients with hyperlipidemia or prior cardiovascular (CV) events. Methods: 
Retrospective population-based cohort study conducted using electronic medical 
records linked to national registers. Patients were included in the study based on a 
prescription of lipid-lowering treatment between January 1, 2006 and December 31, 
2006 or history of CV events (prior to 2006) and followed until December 31, 2012 for 
estimation of LDL-C goal attainment. Patients were stratified into cohorts based on 
CV risk level. Propensity score matching was applied to compare patients with new 
events (myocardial infarction, unstable angina, revascularization, ischemic stroke, 
transient ischemic attack or heart failure) to patients without new events. Results: 
Mean LDL-C at the time of the new CV event (index date) was 100.4 mg/dL for 
patients with CV event history who had a new event (n= 1,101). The mean LDL-C 
for patients without new events in the same cohort (n= 1,304) was 97.4 mg/dL. The 
proportion of patients with CV event history and LDL-C < 70 mg/dL was 20.5% and 
21.5% for patients with and without new events, respectively. The percentage who 
attained the goal of 100 mg/dL was 54.1% and 58.1%, respectively. Mean LDL-C for 
CV risk equivalent (RE) patients with new events (n= 803) was 100.3 mg/dL while 
patients in the same cohort without new events (n= 975) had a mean level of 97.4 mg/
dL. 22.0% of CV RE patients with new events had a LDL-C < 70 mg/dL and 53.8% had 
a level < 100 mg/dL. The corresponding data for CV RE patients without new events 
were 19.1% and 57.7%, respectively. ConClusions: The proportion of patients who 
met LDL-C goals was low, suggesting that current treatment is suboptimal. The pro-
portion of patients who attained the goals was similar in patients with and without 
new events and across CV risk levels.
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objeCtives: To estimate the clinical impact over three years of switching atrial 
fibrillation (AF) patients receiving no treatment or aspirin, or Vitamin K antago-
nist (VKA), to rivaroxaban in China. Methods: A prevalence-based, deterministic 
budget impact model was developed. The number of AF patients was calculated 
based on data from literatures. The baseline risk of events and the efficacy and 
safety data for aspirin and VKA were from meta-analysis. While the efficacy and 
safety data for rivaroxaban were from ROCKET-AF trial. The current treatment pat-
tern was from a large registry study for Chinese AF patients. 9%, 61% and 30% of AF 
patients received no treatment, aspirin and VKA, respectively. We just assumed that 
5% of the patients who received aspirin currently switch to rivaroxaban per year. 
Then the model estimates the number of ischemic stroke (IS), systemic embolisms 
(SE), myocardial infarction (MI), intracranial bleeds (ICH) and major extracranial 
bleeds (ECH) per year. Results: The number of NVAF patients is 4.5 million. For 
those patients, there might be 127,469 major IS events, 34,001 SE events, 9,933 MI 
events, 28,745 ICH events and 56,193 major ECH events under current treatment 
per year. With 5% patients switching to rivaroxaban from aspirin in the first year, 
the IS events reduced 4%, SE events reduced 6% and MI events reduced 2% with 
increased 3% ICH and 1% ECH. To the third year, the IS events continue to reduce 
11%, SE events reduced 17% and MI events reduced 6% with increased 10% ICH and 
4% ECH compared with the current situation. ConClusions: Rivaroxaban may 
decrease the clinical burden of AF in China by reducing the incidence of stroke and 
fatal CV events. Decision-makers can find the exact value of rivaroxaban easily by 
the simple tool in different situations.
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objeCtives: To estimate the clinical impact over three years of switching deep 
vein thrombosis (DVT) patients receiving low molecular weight heparin (LMWH) 
and vitamin K antagonist (VKA) to rivaroxaban. Methods: A prevalence-based, 
deterministic budget impact model was developed. The incidence of DVT patient 
was from literatures. We assumed that 12%, 65% and 23% received treatment for 
3months, 6months and 12months, separately. The efficacy and safety data for 
LMWH+VKA were from meta-analysis. While the efficacy and safety data for rivar-
oxaban were from EINSTEIN-DVT trial. We just assumed that 20% of the patients 
who received LMWH + VKA currently switch to rivaroxaban in the first year and 
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objeCtives: Following an acute deep vein thrombosis (DVT) or pulmonary 
embolism (PE) event, physicians can choose among heparin, vitamin K antago-
nists (VKA), and Non-VKA oral anticoagulants (NOAC) for therapy. We assessed 
patients’ satisfaction with their ongoing anticoagulation treatment. Methods: 
PREFER in VTE (PREvention oF thromboembolic events – European Registry in 
Venous Thromboembolism) is an ongoing non-interventional study in France, 
Germany, Austria, Switzerland, Italy, Spain and UK. The Perception of Anti-Coagulant 
Treatment Questionnaire (PACT-Q2) is a valid and reliable instrument that allows 
the assessment of patients’ satisfaction regarding anticoagulant treatment, as well 
as their opinion about convenience of use. Results: At baseline (BL), a total of 
2311 patients with acute VTE (1366 DVT, 945 PE) met the eligibility criterion of cur-
rent anticoagulation and completed the PACT-Q2 questionnaire. 665 patients were 
eligible for an interim analysis at 6 months: 7.8% have received heparin only, 33.2% 
initial heparin/VKA and 9.0% uninterrupted NOAC. In the “convenience” dimen-
sion, the score (0-100 range) at BL/6 months was 78.9 ±17.62/ 76.2 ±18.20 points for 
heparin only, 81.0 ±16.36/ 80.5 ±16.34 for heparin/VKA, and 88.9 ±12.14/ 93.3 ±7.30 for 
NOACs (all patients: 81.5 ±16.78/ 81.6 ±17.26). Compared to BL, the score improved 
the most in the NOAC group. In the “anticoagulant treatment satisfaction” dimen-
sion, the score at BL/ 6- month was 64.2 ±14.02/64.3 ±16.68 points for heparin only, 
65.8 ±14.92/68.7 ±14.46 for heparin/VKA and 68.2 ±16.65/72.9 ±16.70 for NOACs (all 
patients 65.4 ±15.26/68.5 ±15.76). ConClusions: Overall, patients on current anti-
coagulation reached relatively high values on the convenience scale, but moderate 
values on the satisfaction scale. Patients on NOACs rated their convenience and 
treatment satisfaction substantially higher than patients on heparin/VKA.
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objeCtives: We aimed to understand treatment satisfaction over time under eve-
ryday practice conditions after introduction of NOACs (Non vitamin K antagonist 
oral anticoagulants) in the The PREvention oF thromboembolic events – European 
Registry in Atrial Fibrillation (PREFER in AF). Methods: PREFER in AF documents 
clinical characteristics, management, quality of life and other outcome parameters 
of AF patients. A total of 6412 consecutive patients with ECG-confirmed AF in the 
previous 12 months were followed up prospectively. The ‘Perception of Anticoagulant 
Treatment Questionnaire’ is a valid and reliable instrument to assess patients’ 
expectations (PACT-Q1) and satisfaction regarding anticoagulant treatment, as 
well as patients’ opinion about treatment convenience of use (PACT-Q2). Results: 
A total of 2985 patients were willing to fill out the PACT-Q2 questionnaire both at 
baseline and FU. 1632 of these were on vitamin K antagonists (VKAs), 374 on NOACs, 
203 on antiplatelets (AP), 142 on VKA+AP combinations and 634 on neither treat-
ment. In the “convenience” dimension, the overall score (0-100 range) at FU was 
84.3 ±16.5. The scores ranged from 81.9 in the no NOAC/VKA/AP group (± 18.43), 
84.0 AP (± 16.7), 84.4 NOAC (± 15.9), 85.0 VKA (± 15.9) to 86.8 in the VKA +AP group 
(± 14.13). In the “anticoagulant treatment satisfaction” dimension of the PACT-Q2, 
the overall score was 65.1 ±15.7. The scores ranged from 64.5 in no NOAC/VKA/AP 
(± 14.8), 63.2 in AP group (± 17), 66.0 in NOAC (± 15.05), 64.9 in VKA (± 15.9), to 69.5 in 
VKA +AP group (± 15.8). ConClusions: Overall, patients on current anticoagulation 
achieve relatively high values on the convenience scale, but moderate values on the 
satisfaction scale. While differences in group size and patient characteristics need to 
be taken into account, patients on NOACs compared to patients on VKAs rate their 
convenience and treatment comparable to other treatment schemes.
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objeCtives: Men’s and Women’s health care experiences differ as they age. These 
differences lead to disparate health and treatment outcomes between the genders, 
especially in the area of cardiac health, which has significant disease burden in 
the US. Women experience symptoms that ‘deviate’ from the ones found in a clini-
cian’s guidebook. The emergency room (ER) also serves as a medical space for initial 
diagnosis of heart conditions. Thus, looking at the gender based use of ER prior to 
a cardiac event may help us understand the disparities from a systems perspec-
tive. Cardiac pacemakers are used to treat severe and/or symptomatic bradycardia, 
heart block or a combination of both. This study explored gender differences in 
characteristics and ER diagnoses associated with pacemaker implants in an inpa-
tient setting. Methods: The study used data from the inpatient and emergency 
room hospital discharge data from the Florida HealthCare Utilization Project for 
years 2009 and 2010. Patients with a primary insertion of initial pacemaker and 
with a diagnosis of bradycardia or heart block or both were included. A unique 
patient identifier helped map patients across the inpatient and emergency set-
